European Companies Search Engine

Quick Search Power Search
Tips & Tricks
Our help pages Using the Quick Search and Power Search Overview explain how to use our search engine.

DJS Antibodies Ltd., Oxford

Watch

If you put a company on your watch list, we'll notify you on your email address when there are new publications regarding this company.

This feature is only available to our premium service subscribers.

Learn more about the North Data Premium Service

Dossier

The dossier is a printable PDF file, summarizing information and publications for this company. The creation of dossiers is included in your subscription. After the creation of the dossier is completed, it will be sent to your email address .

Add to dossier (if available):

This feature is only available to our premium service subscribers.

Learn more about the North Data Premium Service

Name

DJS Antibodies Ltd.

Register

Chp
Companies House 09140967

Address

Wood Centre For Innovation Quarry Road, Headington, Oxford OX3 8SB, United Kingdom
Bicester, United Kingdom

Additional info

72.11
Research and experimental development on biotechnology

Financials

Earnings Revenue Employees

Earnings

For this company, Earnings numbers are only available to our premium service subscribers.

Learn more about the North Data Premium Service

Revenue

For this company, Revenue numbers are only available to our premium service subscribers.

Learn more about the North Data Premium Service

Employees

For this company, Employees numbers are only available to our premium service subscribers.

Learn more about the North Data Premium Service

History

Network

Loading network
CSV export

Quarterly Exports in CSV

Now available in CSV format and optimized for applications in AI and Analytics:
North Data's quarterly exports have become the industry standard for company information.

Publications

18 Jun 2024
No longer Director: David Llewellyn
17 Jun 2024
Director: Alice E. Butler
31 Jan 2024
Resolution of allotment of securities
26 Jan 2024 also 14/02/2022, 07/12/2016
Statement of capital following an allotment of shares
25 Sept 2023 also 21/07/2017
Confirmation statement made with updates
8 Aug 2023
Current accounting period extended from 2023-07-31 to 2023-12-31
4 Nov 2022
Resolution of removal of pre-emption rights · Resolution of varying share rights or name …
2 Nov 2022
Statement of capital following an allotment of shares · Change of share class name or designation
26 Oct 2022
Notification of Abbvie Inc. as a person with significant control · Cessation of Oxford Sciences Innovation Plc as a …
24 Oct 2022
Director: Todd Manning, Scott Reents · No longer Director (4)
21 Sept 2022
Annual report for the year ending 31/07/2022 · Balance sheet for 31/07/2022 · Earnings statement for 31/07/2022
3 Aug 2022
Confirmation statement made with updates · Change of details for D David Colin Conway Llewellyn as a person with …
2 Aug 2022
Change of details for Dr Joseph James Illingworth as a person with significant control
28 Jul 2022
Annual report for the year ending 31/07/2021 · Balance sheet for 31/07/2021 · Earnings statement for 31/07/2021
3 Sept 2021
Memorandum and Articles of Association · Resolution of adoption of Articles of Association (ADOPT ARTICLES)
23 Jul 2021 also 24/07/2020, 24/07/2019, 25/07/2018
Confirmation statement made with no updates
16 Jun 2021
Director: John Sørensen Haurum · No longer Director: Uciane Scarlett
15 Jun 2021
Director: Clare E. Terlouw
14 Jun 2021
Address
4 Jun 2021
No longer Director: Pauline Ch. Stasiak
19 Apr 2021
Annual report for the year ending 31/07/2020 · Balance sheet for 31/07/2020 · Earnings statement for 31/07/2020
4 Jan 2021
Memorandum and Articles of Association · Resolution of allotment of securities …
24 Dec 2020
Director: Nan Shen
23 Dec 2020
Director: Uciane Scarlett, Pauline Ch. Stasiak
1 Jun 2020 in Ukri
UK funding (£236,955): Development of a novel therapeutic antibody to treat kidney disease
26 Mar 2020
Annual report for the year ending 31/07/2019 · Balance sheet for 31/07/2019 · Earnings statement for 31/07/2019
31 Jan 2020
Termination of appointment of Andrew James Mclean as a director
17 Apr 2019
Annual report for the year ending 31/07/2018 · Balance sheet for 31/07/2018 · Earnings statement for 31/07/2018
1 Apr 2019 in Ukri
UK funding (£753,934): Antibodies for the treatment of chronic kidney disease: Technical proof of concept
26 Jun 2018
Director: Graeme R. Martin
30 Apr 2018
Annual report for the year ending 31/07/2017 · Balance sheet for 31/07/2017 · Earnings statement for 31/07/2017
27 Apr 2018
Notification of Oxford Sciences Innovation Plc as a person with significant control
23 Apr 2018
Director's details changed for Dr Andrew James Mclean
1 Dec 2017 in Ukri
UK funding (£682,149): Improving cancer immunotherapies: Developing a novel antibody to CXCR2
21 Mar 2017
Annual report for the year ending 31/07/2016 · Balance sheet for 31/07/2016 · Earnings statement for 31/07/2016
27 Oct 2016
Statement of capital following an allotment of shares · Resolution of adoption of Articles of Association (ADOPT …
18 Oct 2016
Reg­is­tra­tion: 21/07/2014 · Capital: £100.00
6 Oct 2016
Director: Andrew James Mclean
26 Jul 2016
Confirmation statement made with updates · Director's details changed for Joseph Illingworth
19 Apr 2016
Annual report for the year ending 31/07/2015 · Balance sheet for 31/07/2015 · Earnings statement for 31/07/2015
1 Nov 2015 in Ukri
UK funding (£24,998): Defining the market for monoclonal antibody development against GPCRs
4 Aug 2015
Capital: £100.00
3 Aug 2015
Director's details changed for Mr David Colin Conway Llewellyn
25 Jun 2015
Address
6 Aug 2014
Address

The data on this page is generated by a fully automated algorithm. It may have errors, and is provided on an "as is" basis with no guarantees of completeness, accuracy, usefulness or timeliness.

Creative Commons License The visualizations for "DJS Antibodies Ltd., Oxford" are provided by North Data and may be reused under the terms of the Creative Commons CC-BY license.

Printing is only available to North Data premium service subscribers.
Close